EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Pharmaceutical Industry in 2024: An Analysis of the FDA Drug Approvals from the Perspective of Molecules

Beatriz G de la Torre iD, Fernando Albericio iD

Molecules · 22.01.2025 · 30 (3) · 482

DOI: 10.3390/molecules30030482 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 22.01.2025. Verfasst von Beatriz G de la Torre und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa. Hauptthemen laut MEDLINE: Drug Approval, Drug Industry. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of KwaZulu-Natal.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The U.S. Food and Drug Administration (FDA) has authorized 50 new drugs in 2024, which matches the average figure for recent years (2018–2023). The approval of 13 monoclonal antibodies (mAbs) sets a new record, with these molecules accounting for more than 25% of all drugs authorized this year. Three proteins have been added to the list of biologics, and with the inclusion of four TIDES (two oligonucleotides and two peptides), only one in three approved drugs this year is a small molecule. As of 2023, no antibody-drug conjugates (ADCs) have reached the market this year. Two deuterated drugs have been approved, bringing the total approvals for this class of compounds to four. This year saw the authorization of two more PEGylated drugs—both peptides—highlighting a renewed interest in this strategy for extending drug half-life, despite the setback caused by the withdrawal of peginesatide from the market in 2014 due to adverse side effects. N-aromatic heterocycles and fluorine atoms are present in two-thirds of all the small molecules approved this year. Herein, the 50 new drugs authorized by the FDA in 2024 are analyzed exclusively on the basis of their chemical structure. They are classified as the following: biologics (antibodies, proteins), TIDES (oligonucleotides and peptides), combined drugs, natural products, F-containing molecules, nitrogen aromatic heterocycles, aromatic compounds, and other small molecules.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug ApprovalDrug IndustryUnited StatesUnited States Food and Drug AdministrationHumansAntibodies, Monoclonal

Stichwörter der Autor:innen

PFASTIDESantibodiesbiologicschemical entitiesdeuterated drugsfluorine-based drugsimagingnatural productsnew chemical entitiesoligonucleotidespeptidespolyfluoroalkyl substances

Substanzen

Antibodies, Monoclonal

Autor:innen und Institutionen

  • School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa.
  • School of Chemistry and Physics, University of KwaZulu-Natal, Durban 4001, South Africa.
  • Department of Organic Chemistry, University of Barcelona, 08028 Barcelona, Spain.

ORCID-Profile: Beatriz G de la Torre, Fernando Albericio

Förderung

  • University of KwaZulu-Natal

Zitieren

APA

de la Torre, B. G., & Albericio, F. (2025). The Pharmaceutical Industry in 2024: An Analysis of the FDA Drug Approvals from the Perspective of Molecules. Molecules, 30(3), 482. https://doi.org/10.3390/molecules30030482

Vancouver

de la Torre BG, Albericio F. The Pharmaceutical Industry in 2024: An Analysis of the FDA Drug Approvals from the Perspective of Molecules. Molecules. 2025;30(3):482. doi:10.3390/molecules30030482

BibTeX
@article{delaTorre2025,
  author = {de la Torre, Beatriz G and Albericio, Fernando},
  title = {The Pharmaceutical Industry in 2024: An Analysis of the FDA Drug Approvals from the Perspective of Molecules},
  journal = {Molecules},
  year = {2025},
  volume = {30},
  number = {3},
  pages = {482},
  doi = {10.3390/molecules30030482}
}
Kostenlos starten →